51 NHS organisations to receive a share of almost £2.8m to help integrate the 2021/22 supported Rapid Uptake Products

Almost £2.8m has been made available to 51 projects in ICSs, CCGs and Trusts across England to help them integrate supported rapid uptake products into everyday practice.

Three projects within the Wessex region have been successful plus two regional awards totalling £500k. 

The Accelerated Access Collaborative (AAC) Rapid Uptake Products (RUP) programme supports stronger adoption and spread of NICE approved proven innovations targeting clinical priorities as set out in the NHS Long Term Plan.

The 2021/22 supported RUPs are:

• Lipid Management, a NICE-endorsed clinical pathway to help reduce cholesterol
• Asthma Biologics, a treatment for severe Asthma
• FeNO testing, which aids diagnosis of Asthma
• Tamoxifen as a preventative treatment for breast cancer

Funding has to date been made available for the first three RUPs and organisations will have the opportunity to apply for funding for Tamoxifen projects from June onwards, please contact Fliss Mitchell at Wessex AHSN for more information. 

Over 170 applications were received, which is the largest response ever to a PTF award. This has meant not every application could be funded but unsuccessful applicants are encouraged to discuss with their local AHSN the support they can offer to help deliver the 2021/22 RUPs.

Here in the Wessex region, please contact Heather Bowles for FeNO, for Biologics, Tamoxifen and Lipids please contact our enquiries email.

For the latest update visit: https://www.england.nhs.uk/aac/what-we-do/how-can-the-aac-help-me/pathway-transformation-fund/